EdH
The $20m cash burn rate includes the cost of the HRV phase II trial. Your calculation implies BTA has another major trial over the subsequent few quarters. With the other drugs predominantly funded by BTA's partners I am not sure where this implied $20m per quarter expenditure will come from. Can you please help me out here?